ReviewCurrent pharmaceutical design2012
Breaking the barrier in stroke: what should we know? A mini-review.
Review in Current pharmaceutical design, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Substance P Reduces Infarct Size and Mortality After Ischemic Stroke, Possibly Through the M2 Polarization of Microglia/Macrophages and Neuroprotection in the Ischemic Rat Brain.Cellular and molecular neurobiology · 2023Article
- Neuroprotective effects of four different fluids on cerebral ischaemia/reperfusion injury in rats through stabilization of the blood-brain barrier.The European journal of neuroscience · 2021Article
- Sirt3 Protects Against Ischemic Stroke Injury by Regulating HIF-1α/VEGF Signaling and Blood-Brain Barrier Integrity.Cellular and molecular neurobiology · 2021Article
- A novel PGAM5 inhibitor LFHP-1c protects blood-brain barrier integrity in ischemic stroke.Acta pharmaceutica Sinica. B · 2021Article
- ELTD1 as a biomarker for multiple sclerosis: Pre-clinical molecular-targeted studies in a mouse experimental autoimmune encephalomyelitis model.Multiple sclerosis and related disorders · 2021Article
- Soluble Receptors Affecting Stroke Outcomes: Potential Biomarkers and Therapeutic Tools.International journal of molecular sciences · 2021Review
- Could the Gut Microbiota Serve as a Therapeutic Target in Ischemic Stroke?Evidence-based complementary and alternative medicine : eCAM · 2021Review
- Anfibatide Preserves Blood-Brain Barrier Integrity by Inhibiting TLR4/RhoA/ROCK Pathway After Cerebral Ischemia/Reperfusion Injury in Rat.Journal of molecular neuroscience : MN · 2020Article
- T-Regulatory Cells Confer Increased Myelination and Stem Cell Activity after Stroke-Induced White Matter Injury.Journal of clinical medicine · 2019Article
- Activation of EphA4 induced by EphrinA1 exacerbates disruption of the blood-brain barrier following cerebral ischemia-reperfusion via the Rho/ROCK signaling pathway.Experimental and therapeutic medicine · 2018Article
- COX-2 contributes to LPS-induced Stat3 activation and IL-6 production in microglial cells.American journal of translational research · 2018Article
- Sac-1004, a vascular leakage blocker, reduces cerebral ischemia-reperfusion injury by suppressing blood-brain barrier disruption and inflammation.Journal of neuroinflammation · 2017Article
- Vectorized nanodelivery systems for ischemic stroke: a concept and a need.Journal of nanobiotechnology · 2017Review
- Role of Hypoxia Inducible Factor 1 in Hyperglycemia-Exacerbated Blood-Brain Barrier Disruption in Ischemic Stroke.Neurobiology of disease · 2016Article
- Injury site-specific targeting of complement inhibitors for treating stroke.Immunological reviews · 2016Review
- Docosahexaenoic acid improves behavior and attenuates blood-brain barrier injury induced by focal cerebral ischemia in rats.Experimental & translational stroke medicine · 2015Article
- Ischemic neurons activate astrocytes to disrupt endothelial barrier via increasing VEGF expression.Journal of neurochemistry · 2014Article
- Article
- Brief overview: Protective roles of astrocyte-derived pentraxin-3 in blood-brain barrier integrity.Brain circulationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The blood-brain barrier (BBB) has been considered as an important regulator of brain homeostasis, and its disturbance has been implicated in the onset and/or evolution of many pathological manifestations of neurodegenerative and inflammatory diseases [1, 2]. In particular, BBB breakdown has been closely associated with the primary insult, as well as the secondary cell death of stroke. Here, we review the pioneering contributions of leading scientists who have vested interest in advancing our understanding of the pivotal role of BBB in stroke, but also exploiting this knowledge in developing novel BBB-based therapeutic regimens to abrogate stroke symptoms. The study of BBB as a fundamental research theme and as a target for clinical applications in stroke can be approached in three main themes namely, basic science research, translational and clinical research, and emerging therapies for BBB repair in stroke. This minireview captures cutting-edge discoveries establishing BBB as a central target for abetting neuroprotection and neurorestoration in stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.